Cart
sales@molnova.com
AMRI-59
CAS No. 923515-92-8
AMRI-59( AMRI 59 | AMRI59 )
Catalog No. M27848 CAS No. 923515-92-8
AMRI-59 is a potent inhibitor of PrxI with anti-tumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 393 | Get Quote |
|
| 10MG | 581 | Get Quote |
|
| 25MG | 888 | Get Quote |
|
| 50MG | 1242 | Get Quote |
|
| 100MG | 1674 | Get Quote |
|
| 500MG | 3348 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAMRI-59
-
NoteResearch use only, not for human use.
-
Brief DescriptionAMRI-59 is a potent inhibitor of PrxI with anti-tumor activity.
-
DescriptionAMRI-59 is a potent inhibitor of PrxI with anti-tumor activity.
-
In Vitro——
-
In Vivo——
-
SynonymsAMRI 59 | AMRI59
-
PathwayOthers
-
TargetOther Targets
-
RecptorLPA1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number923515-92-8
-
Formula Weight401.51
-
Molecular FormulaC25H27N3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC(=O)c1cccc(NC(=O)N2CCC(Cc3ccc(cc3)-n3cccc3)CC2)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Jonathan Ellery, et al. Identification of compounds acting as negative allosteric modulators of the LPA 1 receptor. Eur J Pharmacol. 2018 Aug 15;833:8-15.
molnova catalog
related products
-
Sacituzumab goviteca...
Sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, facilitates the delivery of SN-38. It demonstrates anticancer activity .
-
Glenzocimab
Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis.
-
SC 57461
A potent and selective inhibitor of LTA4 hydrolase (LTA4H) with IC50/Ki of 5 nM/23 nM; inhibits calcium ionophore-induced LTB(4) production in human whole blood (IC50=49 nM).
